Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS). Clinical manifestations of SCD are mainly characterized by chronic hemolysis and acute vaso-occlusive crisis, which are responsible for severe acute and chronic organ damage. SCD is widespread in sub-Saharan Africa, in the Middle East, Indian subcontinent, and some Mediterranean regions. With voluntary population migrations, people harboring the HbS gene have spread globally. In 2006, the World Health Organization recognized hemoglobinopathies, including SCD, as a global public health problem and urged national health systems worldwide to design and establish programs for the prevention and management of SCD. Herein we describe the historical experience of the network of hemoglobinopathy centers and their approach to SCD in Italy, a country where hemoglobinopathies have a high prevalence and where SCD, associated with different genotypes including ß-thalassemia, is present in the native population.

Current challenges in the management of patients with sickle cell disease : A report of the Italian experience / G. Russo, L. De Franceschi, R. Colombatti, P. Rigano, S. Perrotta, V. Voi, G. Palazzi, C. Fidone, A. Quota, G. Graziadei, A. Pietrangelo, V. Pinto, G.B. Ruffo, F. Sorrentino, D. Venturelli, M. Casale, F. Ferrara, L. Sainati, M.D. Cappellini, A. Piga, A. Maggio, G.L. Forni. - In: ORPHANET JOURNAL OF RARE DISEASES. - ISSN 1750-1172. - 14:1(2019), pp. 120.1-120.9. [10.1186/s13023-019-1099-0]

Current challenges in the management of patients with sickle cell disease : A report of the Italian experience

G. Russo;G. Graziadei;V. Pinto;M.D. Cappellini;
2019

Abstract

Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS). Clinical manifestations of SCD are mainly characterized by chronic hemolysis and acute vaso-occlusive crisis, which are responsible for severe acute and chronic organ damage. SCD is widespread in sub-Saharan Africa, in the Middle East, Indian subcontinent, and some Mediterranean regions. With voluntary population migrations, people harboring the HbS gene have spread globally. In 2006, the World Health Organization recognized hemoglobinopathies, including SCD, as a global public health problem and urged national health systems worldwide to design and establish programs for the prevention and management of SCD. Herein we describe the historical experience of the network of hemoglobinopathy centers and their approach to SCD in Italy, a country where hemoglobinopathies have a high prevalence and where SCD, associated with different genotypes including ß-thalassemia, is present in the native population.
Hemoglobin disorder; Hemoglobinopathy; Hydroxyurea; Migrants; Sickle cell screening; Sickle cell disease; Transfusion; Vaso-occlusion crisis
Settore MED/09 - Medicina Interna
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
document.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 932.54 kB
Formato Adobe PDF
932.54 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/648468
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 23
social impact